The Navitas Life Sciences Networks are pleased to confirm the dates for our upcoming Spring forums...

January 24, 2017 Princeton, New Jersey:The Navitas Life Sciences Networks are pleased to confirm the dates for our upcoming Spring forums. At Navitas Life Sciences we have over 15 years’ experience in hosting and facilitating roundtable discussion and forums with Life Sciences leaders, and are well known for our industry leading networks covering CMO, Pharmacovigilance, Labelling, and Regulatory Information Management. Further information and our calendar of events can be found below:

16 March, 2017 in Mumbai: pvindia Forum

Following the successful launch of pvindia in 2016, with participation from: Allergan, Amgen, Bayer, Boehringer Ingelheim, Colgate Palmolive, Ferring, Glenmark, GSK, Hetero Drugs, IPCA Laboratories, Macleods Pharma, Merck and Co, Merck Group, Mylan, Novartis, Novo Nordisk and Roche, we are delighted to be hosting our third event. The meeting will examine the latest PV insights from 3 perspectives:

  • A regulatory perspective – the meeting will start with an overview of the latest global, regional and local PV regulations, with a deep dive on Aggregate Reporting and Risk Management Plans. There will also be a dedicated working session to further explore and review the new PVPI requirements in India.  Dr. Kalaiselvan from PVPI will be participating in the meeting to enable an open dialogue with industry.
  • A PV process perspective – during this Forum we will zoom in on Risk Management Plans, and how to best address the diversity between global and local requirements.
  • The latest technology landscape – the meeting will examine upcoming regulations around technology, such as E2B R3, IDMP, Social Media Scanning and PSURs, as well as exploring latest tools available in PV. 

For further information or to register to attend please contact This email address is being protected from spambots. You need JavaScript enabled to view it.

16 and 17 May, 2017 in London and 07 June, 2017 in New York: labelnet Forum

Established in 2011, labelnet provides a neutral platform for Heads of Labelling and labelling professionals to network, share insights and experiences, benchmark performance, develop best practices across the full lifecycle of labelling, from the definition of company positions (CCDS, CCSI) to local/regional labelling (SmPC, USPI, reference labels, etc.) and, ultimately, to label implementation (artwork, packaging, and electronic media). The Spring agenda will focus on smart labeling and will include smart strategy (development labeling and local intelligence), smart resources (outsourcing and key labeling roles) and smart management (labeling across sectors and back end of the E2E process) and smart technology (one day technology showcase on labeling and RIM key tools and systems (in London only)

For further information or to register to attend please contact This email address is being protected from spambots. You need JavaScript enabled to view it.

18 May, 2017 in London and 08 June, 2017 in New York: rimnet Forum

Discussions around Regulatory Information Management (RIM) within our drug safety and labelling oriented forums, pvnet, pvconnect, and labelnet, led to the initiation of a roundtable to provide a platform to share and discuss the emerging area of RIM.

Established in 2014, the first roundtable was held in May, 2014 in New York and London with participation from 13 companies. The positive feedback from the participants, and the need for further discussion led to events being held twice a year since in both locations. This forum is now a full network focusing on global RIM implementation to provide a platform to discuss organisation, process and technology aspects

For further information or to register to attend please contact This email address is being protected from spambots. You need JavaScript enabled to view it.

07 June, 2017 in New York and 15 June, 2017 in London: pvnet Strategic Summit Forum

Established in 2001, pvnet provides a neutral platform for Pharmacovigilance (PV) leaders facing similar challenges to network, debate, compare performance, and share ideas on how to tackle the latest hot issues – modernising PV in the context of the seismic technology and industry shifts, balancing rising workload and the internal / external resource mix, managing divergent global regulatory requirement, implementing benefit risk management and measurement, deriving value from big data and how to shift the strategic role and contribution of pv. The Spring agenda will focus on implementation of innovative PV programs, with a focus on the role of technology and new sources of data.

For further information or to register to attend please contact This email address is being protected from spambots. You need JavaScript enabled to view it.

07 June, 2017 in New York and 15 June, 2017: pvconnect Forum

Established in 2006, pvconnect provides a neutral platform for PV leaders facing similar challenges to network, debate, compare performance and share ideas on how to tackle the latest hot issues – balancing rising workload with resource constraints, managing increased regulatory scrutiny amid divergent requirements, implementing benefit risk management and measurement, leveraging new data sources and modernising PV in the context of the seismic technology, industry and corporate shifts. Agenda topics for Spring 2017 will include the need to balance compliance with agility; our London forum will be centred on QPPV-related discussions.

For further information or to register to attend please contact This email address is being protected from spambots. You need JavaScript enabled to view it.

08 June, 2017 in New York and 14 June, 2017 in London: pvtech Forum

pvtech is the joint pvnet and pvconnect interest group for individuals responsible for enabling and supporting PV technologies in their organisations.

Our vision is to shape the future of technology in Pharmacovigilance by providing business and technology leaders with an open environment to share challenges, but also discuss alternative solutions and develop best practices that are aligned to the future of Pharmacovigilance. We will be looking at how to increase business value from PV technology investments, as well as delivering new insights and new methods of handling the ever increasing work load, requirements and complexities.

For further information or to register to attend please contact This email address is being protected from spambots. You need JavaScript enabled to view it.

We hope to see you at an event in the Spring.

About Navitas:

The Navitas Life Sciences team has been assembled bringing together the proven expert teams of TAKE Life Sciences and WCI Consulting and, adding to this core, a range of experts from the worlds of Clinical Development, Regulatory, Technology, and Consulting. We have built the Navitas Life Sciences team specifically to deliver insight to our clients, to develop pragmatic solutions together, and to support their deployment and operation. We deliver advise, solutions, and services in Clinical, Regulatory, Safety, and Content Management. We are proud that our legacy businesses have served the sector for some 20 years and have allowed us to work with 100 of the top Life Science companies. Our team have now grown to over 400 staff. We pride ourselves in our role as Expert Navigators. Interpreting market and regulatory change; driving collaboration across companies; seeking the simple solution to the complex problem; investing to enable the changes. Motivated by the success of our clients, we thrive on working together with clients, partners, and each other, across geographies, time zones, and cultures. For more information, visit www.navitas.net/labelnet

 

Latest News

05
Jul2017

From fifteen to future – Navitas Networks 15 year anniversary

Navitas industry networks recently celebrated its milestone 15th year of delivering insights and creating...

09
Jun2017

Life Sciences expert Navitas augments end-to-end capabilities

Navitas, a technology-led Life Sciences services provider across Clinical, Regulatory and Safety, announced that...